Provider review, September 2026
Ozari Health publishes a fifty-row table, one row per state, naming which of its two pharmacies fills there — a list rather than a marketing count, and among the strongest coverage evidence a reader will find. Its weight-loss figures are the weak spot: they are quarterly totals presented as monthly rates, on a plan its own terms say runs three months minimum.
Ozari Health is not a paid partner; this link may earn a commission if that changes. Full disclosure.
Most sellers answer the coverage question with a count. This one prints fifty rows, each naming the state, the pharmacy that fills there and the local support hours.
It also names both pharmacies with their cities and their accreditations, and publishes their coverage gaps rather than hiding them: one is stated to serve all states except nine named ones, the other to serve all fifty.
That is checkable in a way a fifty-state banner never is, and the table was read row by row rather than taken on the strength of its heading.
Both weight-loss treatment pages lead with a per-month figure. The charge underneath it is a single three-month total, and the terms require a three-month minimum.
So the smaller number is an arithmetic average of a commitment, not a monthly payment a reader can stop after one month.
Those rows are recorded here as not monthly rates for that reason. Its NAD+, sermorelin and glutathione plans, by contrast, are genuinely billed monthly and say so.
A toggle offering best-value plans and a new-to-GLP-1 lane implies a second price ladder behind it. Only the three-month starter renders as text, so only the starter is recorded. Visible text or it is not published.
Its savings claims name no baseline. A saving stated with no original figure beside it cannot be checked against anything, so nothing here credits those claims.
Every figure on its comparison page belongs to a named competitor rather than to this seller, and none of those is filed.
Its own words: "Compounded semaglutide is a patient-specific prescription prepared by a state-licensed 503A compounding pharmacy for one person, against one prescription. It is not an FDA-approved finished drug product, it is not a generic of any branded product, and it has not been reviewed by the FDA for safety, effectiveness, or quality."
That is unusually complete — it closes the generic loophole most sellers leave open — and it is quoted here rather than merely summarised.
Its FAQ also calls tirzepatide "the highest-performing GLP-1 medication currently available." That is the seller's superlative, quoted and not endorsed.
Trellis Vitality frames its program around body-composition tracking rather than scale weight, pairing NAD+, glutathione and tesamorelin with at-home biomarker panels and a 90-day re-test, and names its dispensing pharmacy, VialsRX in Houston, by address.
Read the full Trellis Vitality review
Trellis Vitality is not a paid partner; this link may earn a commission if that changes. Full disclosure.
Visit Trellis VitalityThe site tells you. It publishes a fifty-row table naming, for each state, which of its two pharmacies fills there, and it publishes the nine states one of them does not serve.
No. The per-month figure on the treatment pages is a three-month total divided down, and the terms require a three-month minimum.
The seller prints its own price-verification date on the treatment pages, dated to late July 2026. The reading date recorded here is separate and later.
A toggle implies one, but the alternative ladder never renders as text. Only the three-month starter is published, so only that is recorded here.
Ozari Health is not a paid partner; this link may earn a commission if that changes. Full disclosure.